Forbes magazine recognises Kymab's work is 'exciting the big and little guys' and places the company in a select group of UK 'Unicorns'
Kymab is pleased to report that in an article first published on 31 July 2018 Forbes magazine highlighted Kymab as a UK Company that could be a Unicorn in 2019. According to Forbes "Unicorn status (a billion dollar valuation) is the north-star for a lot of startups for different reasons but it is not easy."
The Forbes report says that Kymab "is exciting the big and little guys thanks to its genetic work".
Dr David Chiswell, CEO of Kymab, said: "We are delighted that Forbes recognizes the strength of our pipeline and of our business plan. Our fully human antibodies enable us to create therapeutics and vaccines for some of our most difficult-to-treat diseases."
The report notes that "there are 258 unicorns at the moment … the majority reside in the US and China; but few countries other than the U.K. and India make double digits".
Notes to Editors
The report by Paul Armstrong was originally published as "Here Are The U.K. Companies That Will Be Unicorns In 2019", on 31 July 2018 at: https://www.forbes.com/sites/paularmstrongtech/2018/08/13/here-are-the-uk-companies-that-will-be-unicorns-in-2019/.
About Forbes Magazine
Forbes is an American bi-weekly publication: it features original articles on finance, industry, investing, and marketing topics. Forbes also reports on related subjects such as technology, communications, science, politics, and law. The magazine is well known for its lists and rankings, including of the richest Americans (the Forbes 400), of the world's top companies (the Forbes Global 2000), and The World's Billionaires.
Kymab, a clinical-stage biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.
Kymab's platform has been designed to maximize the diversity of human antibodies produced in response to immunization with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently. Kymab is leveraging its platform for its internal drug discovery programs and in partnership with pharmaceutical companies.
For more information please see http://www.kymab.com.
Kymab is a trademark of Kymab Limited.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.